36 completed, 5 recruiting, 3 terminated, 2 not yet recruiting. 33 Phase 2, 10 Phase 1, 9 Phase 3, 5 Not applicable, 1 Phase 4.
Follow Vehicle Control: new trials by email Literature Review of Vehicle Control trials Research Report on Vehicle Control
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye CAM-101, Vehicle Control - Dry Eye Disease, Dry Eye | Phase 3 | Not yet recruiting | Cambium Bio Limited | 475 | 2026-10-01 | 2026-06-12 |
| A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails 2.4% Topical Terbinafine, 10% Topical Efinaconazole, Vehicle Control - Onychomycosis of Toenail | Phase 2 | Not yet recruiting | Onyx Axiom | 200 | 2026-03-01 | 2026-02-04 |
| A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD) rhPRG4 450ug/ml, Vehicle Control - Ocular Graft Versus Host Disease | Phase 2 | Recruiting | Lubris Bio Pty Ltd | 15 | 2025-09-17 | 2026-10-26 |
| A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE Recombinant Human Proteoglycan 4, Vehicle Control - Sjögren's Syndrome | Phase 2 | Recruiting | Lubris Bio Pty Ltd | 80 | 2025-09-17 | 2026-10-28 |
| Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control - Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders | Phase 2 | Recruiting | University of Illinois Chicago | 24 | 2025-08-01 | 2026-10-28 |
| A Study to Evaluate ENERGI-F705 Tablets in Healthy Volunteers ENERGI-F705 Tablets 60 mg, ENERGI-F705 Tablets 120 mg, Vehicle Control - Health Adult Subjects | Phase 1 | Completed | Energenesis Biomedical Co., Ltd. | 24 | 2025-02-24 | 2026-06-16 |
| A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines YY003, Vehicle Control - Moderate to Severe Glabellar Lines | Phase 2 | Completed | Chongqing Claruvis Pharmaceutical Co., Ltd. | 153 | 2025-01-09 | 2026-09-08 |
| CBD for Knee Osteoarthritis Cannabidiol (CBD) Extract, Placebo - Osteoarthritis, Knee | Phase 1 / Phase 2 | Recruiting | University of Florida | 30 | 2024-06-14 | 2025-09-17 |
| Ozonated Oil Emulsion for Seborrhea in Women Ozonated oil-based cosmetic emulsion, Matched vehicle control - Cosmetic Management of Oily Scalp | Not applicable | Completed | Chadi Khatib | 66 | 2024-04-06 | 2026-10-23 |
| Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers Lotilaner ophthalmic solution, 0.25%, Vehicle control - Demodex Blepharitis | Phase 4 | Completed | Tarsus Pharmaceuticals, Inc. | 145 | 2023-12-27 | 2025-07-02 |
| Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa ALLO-ASC-SHEET, Vehicle Control - Dystrophic Epidermolysis Bullosa | Phase 2 | Unknown | Anterogen Co., Ltd. | 6 | 2023-05-01 | 2024-04-22 |
| Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 RGN-259, Placebo - Neurotrophic Keratopathy | Phase 3 | Recruiting | ReGenTree, LLC | 70 | 2023-04-11 | 2025-12-23 |
| Topical Icariin on Acne and Acne Scars Icariin, Vehicle Control - Acne, Acne Scars | Not applicable | Completed | Seoul National University Hospital | 25 | 2023-03-21 | 2026-03-05 |
| Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study Lotilaner, Vehicle Control - Blepharitis | Phase 3 | Completed | LianBio LLC | 163 | 2022-10-23 | 2024-05-21 |
| Nesvategrast (OTT166) in Diabetic Retinopathy (DR) OTT166, Vehicle control - Diabetic Retinopathy | Phase 2 | Completed | OcuTerra Therapeutics, Inc. | 225 | 2022-07-29 | 2024-08-09 |
| Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects CSB-001 Ophthalmic Solution 0.1%, Vehicle Control - Neurotrophic Keratitis | Phase 1 / Phase 2 | Completed | Claris Biotherapeutics, Inc. | 131 | 2021-08-24 | 2026-05-13 |
| A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia ORTD-1 low dose, ORTD-1 mid dose, ORTD-1 high dose - COVID-19 | Phase 1 / Phase 2 | Withdrawn | Oryn Therapeutics, LLC | 2021-04-01 | 2021-06-14 | |
| Phase I Study of Progerinin in Healthy Volunteers Progerinin, Placebo - Hutchinson-Gilford Progeria Syndrome, Werner Syndrome | Phase 1 | Completed | PRG Science & Technology Co., Ltd. | 64 | 2020-08-24 | 2021-09-22 |
| A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 APL-9, Vehicle Control - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 72 | 2020-05-28 | 2022-03-23 |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 RGN-259, Placebo - Dry Eye Syndromes, Dry Eye | Phase 3 | Completed | ReGenTree, LLC | 700 | 2019-05-24 | 2026-08-28 |
Showing 20 of 50. Sign in to see all of them.
Dry Eye Syndromes (9) · Acne Vulgaris (5) · Graft vs Host Disease (3) · COVID-19 (2) · Epidermolysis Bullosa Dystrophica (2) · Intervertebral Disc Degeneration (2) · Sjogren's Syndrome (2) · Skin Diseases (2) · Acute Lung Injury (1) · Ankle Injuries (1) · Arthritis, Rheumatoid (1) · Back Pain (1) · Blepharitis (1) · Burns (1) · Carcinoma, Non-Small-Cell Lung (1)
ReGenTree, LLC (6) · Bausch Health Americas, Inc. (2) · Cambium Bio Limited (2) · Dermata Therapeutics (2) · Lubris Bio Pty Ltd (2) · Topaz Pharmaceuticals Inc (2) · Actavis Inc. (1) · Actavis Mid-Atlantic LLC (1) · Allergan (1) · Anterogen Co., Ltd. (1) · Apellis Pharmaceuticals, Inc. (1) · Becton, Dickinson and Company (1) · Celularity Incorporated (1) · Cetylite Industries (1) · Chadi Khatib (1)
United States (34) · Australia (4) · Canada (2) · South Korea (2) · United Kingdom (2) · Brazil (1) · China (1) · Hong Kong (1) · India (1) · Italy (1) · Philippines (1) · Poland (1) · Puerto Rico (1) · Spain (1) · Syria (1)
Gail Torkildsen, MD (3) · Abir Saraswat, MD (1) · Ajay J Deshpande, MD (1) · Akhilesh Agarwal, MD (1) · Ali R Djalilian, MD (1) · Alicia Barba, MD (1) · Alicia Bucko, DO (1) · Alpesh Amin, MD (1) · Alur S. Kumar, MD (1) · Amit Luthra, MD (1) · Amit Madan, MD (1) · Ana Rossi, MD (1) · Anilkumar Malik, MD (1) · Anirudh D. Gulanikar, MD (1)
PMID 22712470, PMID 22859988, PMID 23113480, PMID 23337890, PMID 23631911, PMID 25142002, PMID 25826322, PMID 25985246, PMID 27303708, PMID 30660443, PMID 33945627, PMID 35266655, PMID 38052824
3UH3EY031809-04S1 (1)